RAPT Therapeutics (NASDAQ:RAPT) Upgraded at HC Wainwright

HC Wainwright upgraded shares of RAPT Therapeutics (NASDAQ:RAPT) from a neutral rating to a buy rating in a report released on Thursday morning, Marketbeat.com reports. They currently have $10.00 price objective on the stock.

A number of other equities analysts also recently issued reports on RAPT. Wells Fargo & Company dropped their price target on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th. Stifel Nicolaus reissued a “hold” rating and set a $2.00 target price (down previously from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. JPMorgan Chase & Co. cut shares of RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, November 11th. UBS Group cut their price objective on shares of RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating on the stock in a report on Monday, September 9th. Finally, Piper Sandler lowered RAPT Therapeutics from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $8.00 to $2.00 in a report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, RAPT Therapeutics has an average rating of “Hold” and an average target price of $9.56.

RAPT Therapeutics Price Performance

RAPT Therapeutics stock opened at $1.69 on Thursday. The firm has a market capitalization of $59.08 million, a P/E ratio of -0.61 and a beta of 0.07. RAPT Therapeutics has a 1-year low of $0.79 and a 1-year high of $27.35. The company’s 50-day moving average is $1.50 and its 200 day moving average is $2.16.

RAPT Therapeutics (NASDAQ:RAPT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.09. Research analysts anticipate that RAPT Therapeutics will post -2.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On RAPT Therapeutics

Large investors have recently made changes to their positions in the company. Bank of New York Mellon Corp grew its position in shares of RAPT Therapeutics by 24.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 114,590 shares of the company’s stock valued at $349,000 after acquiring an additional 22,175 shares during the period. Los Angeles Capital Management LLC grew its holdings in RAPT Therapeutics by 66.2% in the second quarter. Los Angeles Capital Management LLC now owns 84,586 shares of the company’s stock valued at $258,000 after purchasing an additional 33,692 shares during the period. Acadian Asset Management LLC increased its position in shares of RAPT Therapeutics by 4,183.3% in the second quarter. Acadian Asset Management LLC now owns 467,182 shares of the company’s stock valued at $1,424,000 after buying an additional 456,275 shares in the last quarter. Federated Hermes Inc. lifted its position in shares of RAPT Therapeutics by 188.7% during the 2nd quarter. Federated Hermes Inc. now owns 796,080 shares of the company’s stock valued at $2,428,000 after buying an additional 520,368 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in RAPT Therapeutics by 108.1% in the 2nd quarter. Renaissance Technologies LLC now owns 203,900 shares of the company’s stock valued at $622,000 after acquiring an additional 105,900 shares during the period. 99.09% of the stock is currently owned by institutional investors and hedge funds.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.